Hyku

Hyku Biosciences is pioneering the development of precision covalent medicines. Their approach leverages a proprietary platform that combines chemoproteomics, computational biology, and custom machine learning algorithms. This allows Hyku to target previously undruggable proteins by focusing on non-cysteine amino acids in the proteome. By expanding beyond cysteine, Hyku unlocks a wider range of potential drug targets. Hyku is developing covalent inhibitors for various cancer targets, including KRAS and FGFR mutations often implicated in tumor growth.

Jobs: